Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp
(NQ:
LEXX
)
3.190
-0.120 (-3.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Building a Global Presence with Superior Delivery Technology for Wide Range of Drugs and Active Pharmaceutical Ingredients
December 01, 2023
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows
November 28, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows
November 28, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
November 28, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study
November 27, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study
November 27, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
12 Health Care Stocks Moving In Monday's Intraday Session
November 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 21, 2023
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Generate Sizable License Revenue from IP Growth, Expanding Patent Suite
November 20, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Advance Patented DehydraTECH(TM)
November 15, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Advance Patented DehydraTECH(TM)
November 15, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
November 14, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
November 14, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Patented DehydraTECH(TM) Technology’s Effectiveness on GLP-1 Drugs for Potential Diabetes Treatment and Weight Loss
November 08, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Proven Superior in Research
November 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
November 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
November 01, 2023
Via
Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
November 01, 2023
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END
Via
FinancialNewsMedia
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
November 01, 2023
From
Lexaria Bioscience Corp.
Via
GlobeNewswire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows List of Licensed Partners Following Exclusive Collaboration and License Agreement with SulfoSyn
October 31, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
October 31, 2023
From
Lexaria Bioscience Corp.
Via
GlobeNewswire
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
Via
Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Two New Canadian Patents Amid Continued Efforts to Safeguard the Applicability of Its DehydraTECH(TM) Technology in Multiple Jurisdictions and Sectors
October 26, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Raised $1.6 Million in Latest Investment Round; Looks to Advance DehydraTECH(TM) Research Operations
October 19, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Ongoing Diabetes Study Program to Examine its Patented DehydraTECH(TM) Technology with Launch of Human and Animal Studies for Oral GLP-1 Drugs
October 16, 2023
Via
Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Inks Global Collaboration, License Agreement with SulfoSyn
October 13, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
October 13, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents
October 12, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents
October 12, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.